On August 12th, Gelon Hui announced that its wholly-owned subsidiary Shanghai ChemPartner Pharmatech Co., Ltd. ('Shanghai ChemPartner') recently signed a 'Strategic Cooperation Framework Agreement' with The Hong Kong Polytechnic University ('PolyU'). Both parties plan to explore opportunities for collaborative research and develop new immunotherapeutic drugs. This cooperation will combine the professional knowledge of the academic and pharmaceutical industries, with the long-term goal of benefiting cancer patients.
PolyU provides new targets and professional knowledge of the academic community, while Shanghai ChemPartner fully utilizes its own professional advantages to collaborate on the development of therapeutic drugs. These drugs are designed to target and treat various forms of cancer. This cooperation can achieve a seamless transition from basic research to the development of therapeutic drugs, accelerating the process of bringing new cancer treatment methods to the market. In addition, this cooperation promotes the environment of knowledge and resource sharing, which can further innovate and breakthroughs in cancer treatment. This cooperation can leverage the advantages of both parties to promote the development of cancer treatment.